Mimedx Group, Inc.
MDXG
Surgical & Medical Instruments & Apparatus
Mkt Cap
$1.099BPE
14.83Debt
$19.45MCash
$48.49MEV
$1.07BFCF
$34.77MP/E Ratio
14.83Debt
$19.45MCash
$48.49MEV
$1.07BFCF
$34.77MCharts data: {"Earnings":[{"time":"2014-12-30","value":6220000},{"time":"2015-12-30","value":29446000},{"time":"2016-12-30","value":11974000},{"time":"2017-12-30","value":64727000},{"time":"2018-12-30","value":-29979000},{"time":"2019-12-30","value":-25580000},{"time":"2020-12-30","value":-83328000},{"time":"2021-12-30","value":-16421000},{"time":"2022-12-30","value":-36777000},{"time":"2023-12-30","value":58228000}],"Sales":[{"time":"2014-12-30","value":118223000},{"time":"2015-12-30","value":187296000},{"time":"2016-12-30","value":245015000},{"time":"2017-12-30","value":321139000},{"time":"2018-12-30","value":359111000},{"time":"2019-12-30","value":299255000},{"time":"2020-12-30","value":248234000},{"time":"2021-12-30","value":258615000},{"time":"2022-12-30","value":267841000},{"time":"2023-12-30","value":321477000}],"Net Margins":[{"time":"2014-12-30","value":0.052612435820441034},{"time":"2015-12-30","value":0.15721638475995217},{"time":"2016-12-30","value":0.04887047731771524},{"time":"2017-12-30","value":0.20155446706877708},{"time":"2018-12-30","value":-0.08348115206718813},{"time":"2019-12-30","value":-0.08547893936609247},{"time":"2020-12-30","value":-0.3356832665952287},{"time":"2021-12-30","value":-0.0634959302437987},{"time":"2022-12-30","value":-0.137309075160263},{"time":"2023-12-30","value":0.1811264880535777}],"Assets":[{"time":"2014-12-30","value":109259000},{"time":"2015-12-30","value":135913000},{"time":"2016-12-30","value":193263000},{"time":"2017-12-30","value":121255000},{"time":"2018-12-30","value":122844000},{"time":"2019-12-30","value":167166000},{"time":"2020-12-30","value":202032000},{"time":"2021-12-30","value":187929000},{"time":"2022-12-30","value":171430000},{"time":"2023-12-30","value":239047000}],"Stockholders Equity":[{"time":"2014-12-30","value":89329000},{"time":"2015-12-30","value":107988000},{"time":"2016-12-30","value":133000000},{"time":"2017-12-30","value":73797000},{"time":"2018-12-30","value":49655000},{"time":"2019-12-30","value":34398000},{"time":"2020-12-30","value":-150000},{"time":"2021-12-30","value":82000},{"time":"2022-12-30","value":-17988000},{"time":"2023-12-30","value":142717000}],"ROE":[{"time":"2014-12-30","value":0.06963024325806849},{"time":"2015-12-30","value":0.27267844575323186},{"time":"2016-12-30","value":0.09003007518796992},{"time":"2017-12-30","value":0.8770952748756724},{"time":"2018-12-30","value":-0.6037458463397443},{"time":"2019-12-30","value":-0.7436478865050293},{"time":"2020-12-30","value":555.52},{"time":"2021-12-30","value":-200.2560975609756},{"time":"2022-12-30","value":2.0445296864576386},{"time":"2023-12-30","value":0.40799624431567366}],"ROA":[{"time":"2014-12-30","value":0.06498320504489333},{"time":"2015-12-30","value":0.17926173360899988},{"time":"2016-12-30","value":0.0954450670847498},{"time":"2017-12-30","value":0.38120489876706115},{"time":"2018-12-30","value":-0.03194295203672951},{"time":"2019-12-30","value":-0.12658076403096324},{"time":"2020-12-30","value":-0.22470697711253662},{"time":"2021-12-30","value":-0.026792033161459915},{"time":"2022-12-30","value":-0.1456629528087266},{"time":"2023-12-30","value":0.1552665375428263}]}
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.
Sector
![GKOS Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>GKOS</text></svg>){kind=small}
![GMED Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>GMED</text></svg>){kind=small}
DCF
Discounted Cash Flow Valuation of Mimedx Group, Inc.
Value
Growth
%
%
Discount
%
%
Multiple
| g\r | +10% | +11% | +12% | +13% | +14% |
|---|---|---|---|---|---|
| 0% | 10 | 9 | 8 | 8 | 7 |
| +1% | 11 | 10 | 9 | 8 | 8 |
| +2% | 13 | 11 | 10 | 9 | 8 |
| +3% | 14 | 13 | 11 | 10 | 9 |
| +4% | 17 | 14 | 12 | 11 | 10 |
| Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FCF | $34.77M | $45.2M | $57.5M | $71.56M | $87.06M | $103.5M | $120.2M | $136.2M | $150.6M | $162.3M | $170.4M | $1.704B |
| DCF | $39.3M | $43.48M | $47.05M | $49.78M | $51.46M | $51.96M | $51.21M | $49.23M | $46.14M | $42.12M | $421.2M | |
| Value | $893M | |||||||||||
In the chart Earnings are multiplied by this value.
Earnings Growth 17%
Earnings Stability -26%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 16% | 4.9% | 20% | -8.3% | -8.5% | -34% | -6.3% | -14% | 18% | 22% |
| ROA | 18% | 9.5% | 38% | -3.2% | -13% | -22% | -2.7% | -15% | 16% | 24% |
| ROE | 27% | 9% | 88% | -60% | -74% | 56K% | -20K% | 200% | 41% | 48% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -8.74%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is +4.11%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -6.67%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is +3.08%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is +5.94K%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -2.12K%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | - | - | - | - | -5.27 | 1.55 | 0.56 |
| Debt Equity | - | - | - | 0.00 | 2.23 | -333.33 | 609.76 | -2.78 | 0.36 | 0.12 |
| MIN | ||||||||||
| Graham Stability | - | - | 100% | -85% | -160% | -2.7K% | - | - | - | -2.7K% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is 0.56.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is 6.82.
What is the Graham’s Stability?
Graham’s Stability measure stands at -27.27.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 4% | -2.2% | 9% | 20% | -5.3% |
| Net Income | 25% | - | - | - | 34% |
| Stockholders Equity | 1% | 24% | - | - | -16% |
| FCF | - | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is -2.19%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -5.3%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is +33.58%.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +23.51%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -15.91%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.